Amarin Corp Plc (AMRN)

[HDGabor]

Crestor: After just 1.9 years median (maximum follow-up 5 years) duration, by the study's Independent Data Monitoring Board, because the interim results met the study's predefined stopping criteria (it had been predetermined that it would be unethical to continue the study once it became clear that the patients in one arm of the study had a significantly higher cardiovascular risk than the other arm's patients). Rosuvastatin decreased the relative risk of the primary end point by 44% (HR for rosuvastatin as compared with placebo=0.56; 95% CI, 0.46 to 0.69).

It's not clear for me: Was it at scheduled time (like 60% in R-IT) or not?

+ read it:

http://circ.ahajournals.org/content/91/3/901.full

http://delfini.org/blog/?p=365